[1]
|
Hui, Y.F. and Reitz, J. (2012) Gemcitabine: A Critical Nucleoside for Cancer Therapy. Current Medicinal Chemistry, 19, 1076-1087. https://doi.org/10.2174/092986712799320682
|
[2]
|
Gesto, D.S., Cerqueira, N., Fernandes, P.A. and Ramos, M.J. (2012) Gemcitabine: A Critical Nucleoside for Cancer Therapy. Current Medicinal Chemistry, 19, 1076-1087. https://doi.org/10.2174/092986712799320682
|
[3]
|
Hertel, L.W., Kroin, J.S., Misner, J.W. and Tustin, J.M. (1988) Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2’-difluoro-D-ribofuranosyl Nucleosides. The Journal of Organic Chemistry, 53, 2406-2409.
https://doi.org/10.1021/jo00246a002
|
[4]
|
Hertel, L.W., Boder, G.B., Kroin, J.S., et al. (1990) Evaluation of the Antitumor Activity of Gemcitabine (2’,2’-difluoro-2’-deoxycytidine). Cancer Research, 50, 4417-4422.
|
[5]
|
Moysan, E., Bastiat, G. and Benoit, J.-P. (2013) Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications. Molecular Pharmaceutics, 10, 430-444. https://doi.org/10.1021/mp300370t
|
[6]
|
Abbruzzese, J.L., Grunewald, R., Weeks, E.A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W. and Raber, M.N. (1991) A Phase I Clinical, Plasma, and Cellular Pharmacology Study of Gemcitabine. Journal of Clinical Oncology, 9, 491-498. https://doi.org/10.1200/JCO.1991.9.3.491
|
[7]
|
Hu, G., Li, F., Ouyang, K., et al. (2011) Intrinsic Gemcitabine Re-sistance in a Novel Pancreatic Cancer Cell Line. International Journal of Oncology, 40, 798-806.
|
[8]
|
MMoysaoysan, E., Bastiat, G. and Benoit, J.-P. (2013) Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications. Molecular Pharmaceutics, 10, 430-444. https://doi.org/10.1021/mp300370t
|
[9]
|
Dubey, R.D., Saneja, A., Gupta, P.K. and Gupta, P.N. (2016) Recent Advances in Drug Delivery Strategies for Improved Ther-apeutic Efficacy of Gemcitabine. European Journal of Pharmaceutical Sciences, 93, 147-162.
https://doi.org/10.1016/j.ejps.2016.08.021
|
[10]
|
Dasanu, C.A. (2008) Gemcitabine: Vascular Toxicity and Pro-thrombotic Potential. Expert Opinion on Drug Safety, 7, 703-716. https://doi.org/10.1517/14740330802374262
|
[11]
|
Cavaliere, A., Probst, K.C., Westwell, A.D. and Slusarczyk, M. (2017) Fluorinated Nucleosides as an Important Class of Anticancer and Antiviral Agents. Future Medicinal Chemistry, 9, 1809-1833.
https://doi.org/10.4155/fmc-2017-0095
|
[12]
|
Reddy, L.H. and Couvreur, P. (2009) Squalene: A Natural Triterpene for Use in Disease Management and Therapy. Advanced Drug Delivery Reviews, 61, 1412-1426. https://doi.org/10.1016/j.addr.2009.09.005
|
[13]
|
Sobot, D., Mura, S., Yesylevskyy, S.O., et al. (2017) Conjugation of Squalene to Gemcitabine as Unique Approach Exploiting Endogenous Lipoproteins for Drug Delivery. Nature Com-munications, 8, Article No. 15678.
https://doi.org/10.1038/ncomms15678
|
[14]
|
Réjiba, S., Reddy, L.H., Bigand, C., et al. (2011) Squalenoyl Gemcita-bine Nanomedicine Overcomes the Low Efficacy of Gemcitabine Therapy in Pancreatic Cancer. Nanomedicine: Nano-technology, Biology and Medicine, 7, 841-849.
https://doi.org/10.1016/j.nano.2011.02.012
|
[15]
|
Harivardhan Reddy, L., Ferreira, H., Dubernet, C., et al. (2008) Oral Absorption and Tissue Distribution of a New Squalenoyl Anticancer Nanomedicine. Journal of Nanoparticle Re-search, 10, 887-891.
https://doi.org/10.1007/s11051-007-9322-7
|
[16]
|
Suk, J.S., Xu, Q., Kim, N., Hanes, J. and Ensign, L.M. (2016) PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery. Advanced Drug Delivery Reviews, 99, 28-51.
https://doi.org/10.1016/j.addr.2015.09.012
|
[17]
|
Zhao, X., Si, J., Huang, D., Li, K., Xin, Y. and Sui, M. (2020) Application of Star Poly(ethylene glycol) Derivatives in Drug Delivery and Controlled Release. Journal of Controlled Release, 323, 565-577.
https://doi.org/10.1016/j.jconrel.2020.04.039
|
[18]
|
Mero, A., Clementi, C., Veronese, F.M. and Pasut, G. (2011) Covalent Conjugation of Poly(Ethylene Glycol) to Proteins and Peptides: Strategies and Methods. Bioconjugation Pro-tocols, 751, 95-129.
https://doi.org/10.1007/978-1-61779-151-2_8
|
[19]
|
Adema, A.D., Bijnsdorp, I.V., Sandvold, M.L., Verheul, H.M. and Peters, G.J. (2009) Innovations and Opportunities to Improve Conventional (Deoxy)nucleoside and Fluoropyrimi-dine Analogs in Cancer. Current Medicinal Chemistry, 16, 4632-4643. https://doi.org/10.2174/092986709789878229
|
[20]
|
Bergman, A.M., Adema, A.D., Balzarini, J., et al. (2011) Anti-proliferative Activity, Mechanism of Action and Oral Antitumor Activity of CP-4126, a Fatty Acid Derivative of Gem-citabine, in in Vitro and in Vivo Tumor Models. Investigational New Drugs, 29, 456-466. https://doi.org/10.1007/s10637-009-9377-7
|
[21]
|
Pradere, U., Garnier-Amblard, E.C., Coats, S.J., Amblard, F. and Schinazi, R.F. (2014) Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs. Chemical Reviews, 114, 9154-9218. https://doi.org/10.1021/cr5002035
|
[22]
|
Blagden, S.P., Rizzuto, I., Suppiah, P., et al. (2018) An-ti-Tumour Activity of a First-in-Class Agent NUC-1031 in Patients with Advanced Cancer: Results of a Phase I Study. British Journal of Cancer, 119, 815-822.
https://doi.org/10.1038/s41416-018-0244-1
|
[23]
|
Kazmi, F., Nicum, S., Roux, R.L., et al. (2021) A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clin-ical Cancer Research, 27, 3028-3038.
https://doi.org/10.1158/1078-0432.CCR-20-4403
|